FDA approves first cardiac lead for new type of conduction system pacing
Medtronic announced its cardiac lead received an expanded indication from the FDA for left bundle branch area conduction system pacing for the treatment of bradycardia.
Conduction system pacing ensures that pacing closely mimics the heart's physiologic contractions and allows the ventricles to work in coordination while avoiding complications sometimes associated with traditional pacing methods, according to a press release issued by the company.
The cardiac lead (SelectSecure MRI SureScan Model 3830) was approved in 2018 for His bundle pacing, a form of conduction system pacing, and has now become the first lead approved for left bundle branch area pacing, another form of conduction system pacing, as an alternative to apical pacing in the right ventricle, according to the release.
"Conduction system pacing is more like simulating natural activation and can yield positive outcomes for patients," Pugazhendhi Vijayaraman, MD, FHRS, director of electrophysiology at Geisinger Heart Institute in Wilkes-Barre, Pennsylvania, said in the release. "This approval signals to physicians that the Model 3830 lead is safe and effective for patients for conduction system pacing, and it may encourage more physicians to learn the procedure."
Collapse
Read more about